Annual Cash & Cash Equivalents
$16.29 M
-$5.53 M-25.36%
December 31, 2023
Summary
- As of February 7, 2025, SBFM annual cash & cash equivalents is $16.29 million, with the most recent change of -$5.53 million (-25.36%) on December 31, 2023.
- During the last 3 years, SBFM annual cash & cash equivalents has risen by +$15.30 million (+1545.85%).
- SBFM annual cash & cash equivalents is now -99.86% below its all-time high of $11.43 billion, reached on December 1, 2000.
Performance
SBFM Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$12.21 M
+$699.00 K+6.07%
September 30, 2024
Summary
- As of February 7, 2025, SBFM quarterly cash and cash equivalents is $12.21 million, with the most recent change of +$699.00 thousand (+6.07%) on September 30, 2024.
- Over the past year, SBFM quarterly cash and cash equivalents has dropped by -$6.64 million (-35.23%).
- SBFM quarterly cash and cash equivalents is now -70.75% below its all-time high of $41.73 million, reached on June 1, 2022.
Performance
SBFM Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SBFM Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -25.4% | -35.2% |
| 3 y3 years | +1545.8% | -38.1% |
| 5 y5 years | +10000.0% | -38.1% |
SBFM Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -25.4% | +696.6% | -70.8% | +496.9% |
| 5 y | 5-year | -25.4% | >+9999.0% | -70.8% | >+9999.0% |
| alltime | all time | -99.9% | >+9999.0% | -70.8% | >+9999.0% |
Sunshine Biopharma Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $12.21 M(+6.1%) |
| Jun 2024 | - | $11.51 M(-34.0%) |
| Mar 2024 | - | $17.43 M(+7.0%) |
| Dec 2023 | $16.29 M(-25.4%) | $16.29 M(-13.6%) |
| Sep 2023 | - | $18.85 M(-4.5%) |
| Jun 2023 | - | $19.73 M(+2.3%) |
| Mar 2023 | - | $19.29 M(-11.6%) |
| Dec 2022 | $21.83 M(+967.2%) | $21.83 M(-46.2%) |
| Sep 2022 | - | $40.56 M(-2.8%) |
| Jun 2022 | - | $41.73 M(+216.7%) |
| Mar 2022 | - | $13.18 M(+544.3%) |
| Dec 2021 | $2.05 M(+106.6%) | - |
| Dec 2021 | - | $2.05 M(-14.3%) |
| Sep 2021 | - | $2.39 M(+37.5%) |
| Jun 2021 | - | $1.74 M(-3.4%) |
| Mar 2021 | - | $1.80 M(+81.5%) |
| Dec 2020 | $989.90 K(+2344.2%) | $989.90 K(+102.6%) |
| Sep 2020 | - | $488.70 K(+470.9%) |
| Jun 2020 | - | $85.60 K(+692.6%) |
| Mar 2020 | - | $10.80 K(-73.3%) |
| Dec 2019 | $40.50 K(-63.3%) | $40.50 K(-50.6%) |
| Sep 2019 | - | $82.00 K(+119.8%) |
| Jun 2019 | - | $37.30 K(-60.8%) |
| Mar 2019 | - | $95.10 K(-13.9%) |
| Dec 2018 | $110.50 K(+2.8%) | $110.50 K(+138.1%) |
| Sep 2018 | - | $46.40 K(+27.5%) |
| Jun 2018 | - | $36.40 K(-65.3%) |
| Mar 2018 | - | $104.80 K(-2.5%) |
| Dec 2017 | $107.50 K(+87.0%) | $107.50 K(-42.8%) |
| Sep 2017 | - | $188.10 K(+46.0%) |
| Jun 2017 | - | $128.80 K(+653.2%) |
| Mar 2017 | - | $17.10 K(-70.3%) |
| Dec 2016 | $57.50 K(+13.2%) | $57.50 K(+163.8%) |
| Sep 2016 | - | $21.80 K(-70.5%) |
| Jun 2016 | - | $73.90 K(-40.1%) |
| Mar 2016 | - | $123.30 K(+142.7%) |
| Dec 2015 | $50.80 K | $50.80 K(-59.4%) |
| Sep 2015 | - | $125.20 K(-20.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2015 | - | $157.20 K(+5.7%) |
| Mar 2015 | - | $148.70 K(+3.7%) |
| Dec 2014 | $143.40 K(+359.6%) | $143.40 K(-17.5%) |
| Sep 2014 | - | $173.90 K(+352.9%) |
| Jun 2014 | - | $38.40 K(-45.5%) |
| Mar 2014 | - | $70.50 K(+126.0%) |
| Dec 2013 | $31.20 K(-76.5%) | $31.20 K(-56.1%) |
| Sep 2013 | - | $71.00 K(-54.7%) |
| Jun 2013 | - | $156.60 K(-38.8%) |
| Mar 2013 | - | $255.90 K(+93.0%) |
| Dec 2012 | $132.60 K(+118.5%) | $132.60 K(-48.1%) |
| Sep 2012 | - | $255.40 K(+304.1%) |
| Jun 2012 | - | $63.20 K(+64.6%) |
| Mar 2012 | - | $38.40 K(-36.7%) |
| Dec 2011 | $60.70 K(-62.6%) | $60.70 K(-66.0%) |
| Sep 2011 | - | $178.50 K(+76.4%) |
| Jun 2011 | - | $101.20 K(-14.3%) |
| Mar 2011 | - | $118.10 K(-27.3%) |
| Dec 2010 | $162.40 K(+44.9%) | $162.40 K(+50.2%) |
| Sep 2010 | - | $108.10 K(+563.2%) |
| Jun 2010 | - | $16.30 K(-44.0%) |
| Mar 2010 | - | $29.10 K(-83.8%) |
| Dec 2009 | $112.10 K(>+9900.0%) | - |
| Oct 2009 | - | $179.80 K(>+9900.0%) |
| Jul 2009 | $600.00(-86.4%) | $600.00(0.0%) |
| Apr 2009 | - | $600.00(-45.5%) |
| Jan 2009 | - | $1100.00(-45.0%) |
| Oct 2008 | - | $2000.00(-54.5%) |
| Jul 2008 | $4400.00(-70.5%) | $4400.00(0.0%) |
| Apr 2008 | - | $4400.00(-10.2%) |
| Jan 2008 | - | $4900.00(-38.0%) |
| Oct 2007 | - | $7900.00 |
| Jul 2007 | $14.90 K(-100.0%) | - |
| Dec 2003 | $1.95 B(+25.4%) | - |
| Dec 2002 | $1.56 B(-76.7%) | - |
| Dec 2001 | $6.67 B(-41.6%) | - |
| Dec 2000 | $11.43 B(+182.7%) | - |
| Dec 1999 | $4.04 B(+48.8%) | - |
| Dec 1998 | $2.72 B | - |
FAQ
- What is Sunshine Biopharma annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Sunshine Biopharma?
- What is Sunshine Biopharma annual cash & cash equivalents year-on-year change?
- What is Sunshine Biopharma quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Sunshine Biopharma?
- What is Sunshine Biopharma quarterly cash and cash equivalents year-on-year change?
What is Sunshine Biopharma annual cash & cash equivalents?
The current annual cash & cash equivalents of SBFM is $16.29 M
What is the all time high annual cash & cash equivalents for Sunshine Biopharma?
Sunshine Biopharma all-time high annual cash & cash equivalents is $11.43 B
What is Sunshine Biopharma annual cash & cash equivalents year-on-year change?
Over the past year, SBFM annual cash & cash equivalents has changed by -$5.53 M (-25.36%)
What is Sunshine Biopharma quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SBFM is $12.21 M
What is the all time high quarterly cash and cash equivalents for Sunshine Biopharma?
Sunshine Biopharma all-time high quarterly cash and cash equivalents is $41.73 M
What is Sunshine Biopharma quarterly cash and cash equivalents year-on-year change?
Over the past year, SBFM quarterly cash and cash equivalents has changed by -$6.64 M (-35.23%)